Pfizer Inc. (NYSE:PFE) Shares Sold by Sargent Investment Group LLC

Sargent Investment Group LLC cut its position in shares of Pfizer Inc. (NYSE:PFE) by 13.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,557 shares of the biopharmaceutical company’s stock after selling 1,150 shares during the quarter. Sargent Investment Group LLC’s holdings in Pfizer were worth $219,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Pfizer in the first quarter valued at about $315,000. Dorsey & Whitney Trust CO LLC grew its position in Pfizer by 16.0% in the first quarter. Dorsey & Whitney Trust CO LLC now owns 72,467 shares of the biopharmaceutical company’s stock valued at $2,011,000 after acquiring an additional 9,989 shares in the last quarter. Forum Financial Management LP raised its stake in shares of Pfizer by 1.8% during the first quarter. Forum Financial Management LP now owns 57,342 shares of the biopharmaceutical company’s stock valued at $1,591,000 after purchasing an additional 1,033 shares during the period. M&G Plc acquired a new position in shares of Pfizer during the first quarter worth $19,885,000. Finally, Poehling Capital Management INC. grew its holdings in Pfizer by 9.3% during the 1st quarter. Poehling Capital Management INC. now owns 54,416 shares of the biopharmaceutical company’s stock valued at $1,510,000 after purchasing an additional 4,609 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction on Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Pfizer Trading Down 2.6 %

NYSE:PFE opened at $26.02 on Friday. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business has a 50 day simple moving average of $28.76 and a 200 day simple moving average of $28.67. The firm has a market capitalization of $147.46 billion, a P/E ratio of 35.16, a P/E/G ratio of 0.85 and a beta of 0.67.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.17) earnings per share. Equities research analysts predict that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 6.46%. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Analyst Ratings Changes

PFE has been the subject of a number of analyst reports. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Sanford C. Bernstein started coverage on Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price for the company. Finally, StockNews.com upgraded shares of Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Eight equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and a consensus price target of $33.58.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.